Kathryn Angela Palasis

Ms. Kathryn Angela Palasis

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
BBBeatriz Blanco
Beatriz Blanco
KPKathryn Angela Palasis
Kathryn Angela Palasis
AAAlaknanda Adwal
Alaknanda Adwal
DCDavid F. Callen
David F. Callen
Andrew AbellAndrew Abell
Andrew Abell

Verified
Journal Article
Open access
PDF file
KPKathryn Angela Palasis
Kathryn Angela Palasis
NLNoor Lokman
Noor Lokman
BQBryden C. Quirk
Bryden C. Quirk
AAAlaknanda Adwal
Alaknanda Adwal
LSLoretta Scolaro
Loretta Scolaro
Andrew AbellAndrew Abell
Andrew Abell
Local activation of an anti-cancer drug when and where needed can improve selectivity and reduce undesirable side effects. Photoswitchable drugs can be selectively switched between active and inactive states by illumination with light; however, the clinical development of these drugs has been restricted by the difficulty in delivering light deep into tissue where needed. Optical fibres have great potential for light delivery in vivo, but their use in facilitating photoswitching in anti-cancer compounds has not yet been explored. In this paper, a photoswitchable chemotherapeutic is switched using an optical fibre, and the cytotoxicity of each state is measured against HCT-116 colorectal cancer cells. The performance of optical-fibre-enabled photoswitching is characterised through its dose response. The UV–Vis spectra confirm light delivered by an optical fibre effectively enables photoswitching. The activated drug is shown to be twice as effective as the inactive drug in causing cancer cell death, characterised using an MTT assay and fluorescent microscopy. This is the first study in which a photoswitchable anti-cancer compound is switched using an optical fibre and demonstrates the feasibility of using optical fibres to activate photoswitchable drugs for potential future clinical applications.